<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>TGF-beta is a potent inducer of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in many Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we characterize this apoptotic process in the EBV-negative BL41 cell line </plain></SENT>
<SENT sid="2" pm="."><plain>Induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was detected as early as 8 h after TGF-beta treatment, as assayed by TUNEL and poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase cleavage </plain></SENT>
<SENT sid="3" pm="."><plain>FACS analysis demonstrates that this proceeds predominately from the G1, but also from the G2/M phases of the cell cycle </plain></SENT>
<SENT sid="4" pm="."><plain>We observed no early detectable changes in the steady-state levels of Bcl-2 and several of its family members after TGF-beta treatment </plain></SENT>
<SENT sid="5" pm="."><plain>We detected cleavage of caspases 2, 3, 7, 8, and 9 into their active subunits </plain></SENT>
<SENT sid="6" pm="."><plain>Consistent with the involvement of these enzymes in TGF-beta-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, the broad spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(Ome)-flouromethylketone (ZVAD-fmk) blocked TGF-beta-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and revealed a G1 arrest in treated cells </plain></SENT>
<SENT sid="7" pm="."><plain>Use of specific caspase inhibitors revealed that the induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is caspase 8 dependent, but caspase 3 independent </plain></SENT>
<SENT sid="8" pm="."><plain>Activation of caspase 8 has been shown to be a critical event in <z:hpo ids='HP_0011420'>death</z:hpo> receptor-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>However, TGF-beta treatment of BL41 cells was found not to affect the cell surface expression of Fas, TNF-R1, DR3, DR4, or DR5, or the steady-state expression levels of Fas ligand, TNF-R1, DR3, DR4, and DR5 </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, blocking experiments indicated that TGF-beta-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is not dependent on Fas ligand, TNF-alpha, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp>-like <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand, or TNF-like weak inducer of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> signaling </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, it appears that TGF-beta induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines via caspase 8 in a <z:hpo ids='HP_0011420'>death</z:hpo> receptor-independent fashion </plain></SENT>
</text></document>